Abstract
The use of calcium channel blockers was shown to be effective in the treatment of symptomatic and, more recently, of asymptomatic myocardial ischemia. In this continuing study we evaluated the efficacy of nisoldipine as a new calcium channel blocking agent in reducing the frequency and duration of episodes of silent myocardial ischemia. From the preliminary results in five patients, nisoldipine promises to treat episodes of silent myocardial ischemia effectively and thus to increase exercise tolerance.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have